Stock CRBX CARBIOTIX AB
Add to a list
To use this feature you must be a member
Log inSign up

Financials Carbiotix AB

Equities

CRBX

SE0013016128

Biotechnology & Medical Research

End-of-day quote NORDIC GROWTH MARKET
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
0.082 SEK -0.73% Intraday chart for Carbiotix AB +30.99% -79.50%
Apr. 25 Carbiotix AB Signs First NutraCycle Joint Development Agreement with Leading Nordic Plant-Based Food & Beverage Producer CI
Apr. 04 Carbiotix Kicks Off Pilot Study for NutraCycle Service MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023
Capitalization 1 49.78 132.8 161.6 57.42 8.294
Enterprise Value (EV) 1 42.99 125.1 154.2 50.21 5.635
P/E ratio -9.2 x -22.2 x -15.4 x -4.71 x -0.62 x
Yield - - - - -
Capitalization / Revenue 14.2 x 35.3 x 50 x 18.4 x 1.93 x
EV / Revenue 12.3 x 33.2 x 47.8 x 16.1 x 1.31 x
EV / EBITDA - - -14,807,643 x -4,135,198 x -429,581 x
EV / FCF -6.65 x -18.2 x -13.7 x -5.38 x -0.64 x
FCF Yield -15% -5.49% -7.32% -18.6% -156%
Price to Book 3.85 x 7.85 x 7.58 x 2.51 x 0.44 x
Nbr of stocks (in thousands) 8,583 11,083 12,333 14,356 20,736
Reference price 2 5.800 11.98 13.10 4.000 0.4000
Announcement Date 4/3/20 4/2/21 4/1/22 4/28/23 4/2/24
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 4.389 3.499 3.766 3.23 3.114 4.293
EBITDA - - - -10.42 -12.14 -13.12
EBIT 1 -1.994 -5.396 -5.978 -10.47 -12.25 -13.3
Operating Margin -45.44% -154.23% -158.71% -324.06% -393.43% -309.89%
Earnings before Tax (EBT) 1 -2.018 -5.408 -5.984 -10.48 -12.25 -13.48
Net income 1 -2.018 -5.408 -5.984 -10.48 -12.25 -13.48
Net margin -45.98% -154.58% -158.87% -324.32% -393.46% -313.95%
EPS 2 -0.2300 -0.6301 -0.5400 -0.8494 -0.8500 -0.6500
Free Cash Flow 1 -2.557 -6.468 -6.869 -11.29 -9.331 -8.766
FCF margin -58.25% -184.87% -182.37% -349.38% -299.66% -204.17%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 4/3/20 4/3/20 4/2/21 4/1/22 4/28/23 4/2/24
1SEK in Million2SEK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 1.28 6.79 7.64 7.32 7.21 2.66
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -2.56 -6.47 -6.87 -11.3 -9.33 -8.77
ROE (net income / shareholders' equity) -65.4% -62.7% -40.1% -54.8% -55.4% -64.9%
ROA (Net income/ Total Assets) -31.5% -35.9% -23.1% -30.9% -31% -33.2%
Assets 1 6.4 15.04 25.85 33.87 39.52 40.55
Book Value Per Share 2 0.2000 1.510 1.530 1.730 1.590 0.9000
Cash Flow per Share 2 0.0700 0.8000 0.6900 0.5900 0.5000 0.1300
Capex - - - 0.3 0.51 0.22
Capex / Sales - - - 9.41% 16.4% 5.01%
Announcement Date 4/3/20 4/3/20 4/2/21 4/1/22 4/28/23 4/2/24
1SEK in Million2SEK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
CARBIOTIX AB Stock Carbiotix AB
-79.50% 1.35M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. CRBX Stock
  4. Financials Carbiotix AB